See more : Hafnia Limited (HAFNI.OL) Income Statement Analysis – Financial Results
Complete financial analysis of Checkmate Pharmaceuticals, Inc. (CMPI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Checkmate Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Bannix Acquisition Corp. (BNIXR) Income Statement Analysis – Financial Results
- Vama Industries Limited (VAMA.BO) Income Statement Analysis – Financial Results
- Phoenix Group Holdings plc (PHNX.L) Income Statement Analysis – Financial Results
- FCCC, Inc. (FCIC) Income Statement Analysis – Financial Results
- Ovaro Kiinteistösijoitus Oyj (OVARO.HE) Income Statement Analysis – Financial Results
Checkmate Pharmaceuticals, Inc. (CMPI)
About Checkmate Pharmaceuticals, Inc.
Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. Checkmate Pharmaceuticals, Inc. has strategic alliances with Merck KGaA and Pfizer. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. As of May 27, 2022, Checkmate Pharmaceuticals, Inc. operates as a subsidiary of Regeneron Pharmaceuticals, Inc.
| Metric | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 45.82M | 26.72M | 24.25M | 18.17M |
| General & Administrative | 15.65M | 10.19M | 4.64M | 2.82M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 15.65M | 10.19M | 4.64M | 2.82M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 61.47M | 36.90M | 28.89M | 20.99M |
| Cost & Expenses | 61.47M | 36.90M | 28.89M | 20.99M |
| Interest Income | 100.00K | 79.00K | 197.00K | 180.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 66.00K | 188.00K | 597.00K | 180.00K |
| EBITDA | -61.34M | -36.72M | -28.29M | -20.81M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -61.41M | -36.90M | -28.89M | -20.99M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 0.00 | -4.00K | 597.00K | 180.00K |
| Income Before Tax | -61.41M | -36.91M | -28.29M | -20.81M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -4.00K | 0.00 | 0.00 |
| Net Income | -61.41M | -36.91M | -28.29M | -20.81M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -6.42 | -3.86 | -3.44 | -2.53 |
| EPS Diluted | -6.42 | -3.86 | -3.44 | -2.53 |
| Weighted Avg Shares Out | 9.56M | 9.56M | 8.22M | 8.22M |
| Weighted Avg Shares Out (Dil) | 9.56M | 9.56M | 8.22M | 8.22M |
Kuros Biosciences: Completion of the Acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals Triggers a $5 Million Milestone Payment
Ad-hoc announcement pursuant to Article 53 of the SIX listing rules
CHECKMATE PHARMACEUTICALS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkmate Pharmaceuticals, Inc. - CMPI
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Checkmate Pharmaceuticals, Inc. (NasdaqGM: CMPI) to Regeneron Pharmaceuticals, Inc. (NasdaqGS: REGN)....
CHECKMATE PHARMACEUTICALS INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkmate Pharmaceuticals, Inc. - CMPI
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Checkmate Pharmaceuticals, Inc. (NasdaqGM: CMPI) to Regeneron Pharmaceuticals, Inc. (NasdaqGS: REGN)....
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates PSB, FSI, TWTR
NEW YORK , April 26, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: PS Business Parks,...
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Checkmate Pharmaceuticals, Inc. Buyout
Wilmington, Delaware--(Newsfile Corp. - April 20, 2022) - Rigrodsky Law, P.A. is investigating Checkmate Pharmaceuticals, Inc. ("Checkmate") (NASDAQ: CMPI) regarding possible breaches of fiduciary duties and other violations of law related to Checkmate's agreement to be acquired by Regeneron Pharmaceuticals,...
SHAREHOLDER ALERT: Weiss Law Investigates Checkmate Pharmaceuticals, Inc.
NEW YORK , April 19, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Checkmate Pharmaceuticals, Inc. ("Checkmate" or the "Company") (NASDAQ: CMPI), in connection with the proposed...
Why Checkmate Pharmaceuticals Stock Is Rocketing Higher Today
Checkpoint Pharmaceuticals lands a premium-rich buyout offer from biotech heavyweight Regeneron.
Why Is Checkmate Pharmaceuticals (CMPI) Stock Up 300% Today?
Checkmate Pharmaceuticals (CMPI) stock is rocketing higher on Tuesday following news that Regeneron Pharmaceuticals (REGN) is acquiring it. The post Why Is Checkmate Pharmaceuticals (CMPI) Stock Up 300% Today?
Why Checkmate Pharmaceuticals Shares Are Skyrocketing
Checkmate Pharmaceuticals Inc (NASDAQ: CMPI) shares are trading higher by 328.40% to $10.41 during Tuesday's pre-market session after Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced a deal to acquire the company for $10.50 per share in cash. Checkmate's lead investigational candidate.
Checkmate Pharma Shares Skyrocket Over 300% On Regeneron $250M Acquisition Deal
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) will acquire Checkmate Pharmaceuticals Inc (NASDAQ: CMPI) for $10.50 per share, equivalent to a total equity value of approximately $250 million. Checkmate is a clinical-stage biopharmaceutical company focused on proprietary.
Source: https://incomestatements.info
Category: Stock Reports